Free Trial
NASDAQ:PBYI

Puma Biotechnology (PBYI) Stock Price, News & Analysis

Puma Biotechnology logo
$3.55 -0.01 (-0.28%)
Closing price 07/3/2025 03:21 PM Eastern
Extended Trading
$3.54 0.00 (-0.14%)
As of 07/3/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Puma Biotechnology Stock (NASDAQ:PBYI)

Key Stats

Today's Range
$3.53
$3.61
50-Day Range
$2.90
$3.72
52-Week Range
$2.23
$4.13
Volume
127,438 shs
Average Volume
414,099 shs
Market Capitalization
$176.19 million
P/E Ratio
4.61
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Puma Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

PBYI MarketRank™: 

Puma Biotechnology scored higher than 84% of companies evaluated by MarketBeat, and ranked 502nd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Puma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Puma Biotechnology has received no research coverage in the past 90 days.

  • Read more about Puma Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Puma Biotechnology are expected to grow by 22.58% in the coming year, from $0.31 to $0.38 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Puma Biotechnology is 4.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Puma Biotechnology is 4.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

  • Price to Book Value per Share Ratio

    Puma Biotechnology has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Puma Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    7.19% of the float of Puma Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Puma Biotechnology has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Puma Biotechnology has recently decreased by 3.60%, indicating that investor sentiment is improving.
  • Dividend Yield

    Puma Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Puma Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.19% of the float of Puma Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Puma Biotechnology has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Puma Biotechnology has recently decreased by 3.60%, indicating that investor sentiment is improving.
  • News Sentiment

    Puma Biotechnology has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Puma Biotechnology this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for PBYI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $311,563.00 in company stock.

  • Percentage Held by Insiders

    23.30% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Puma Biotechnology's insider trading history.
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Stock News Headlines

Something very strange is happening...
What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone noticed when the U.S. Senate granted sweeping powers to a Harvard economist who has some dangerous ideas about the U.S. dollar. Now, he's issued a blueprint for what a coming "Mar-a-Lago Accord" could look like. One analyst who predicted the 2008 crisis says this plan could see the dollar fall in value by 40% in months and become a national nightmare.
See More Headlines

PBYI Stock Analysis - Frequently Asked Questions

Puma Biotechnology's stock was trading at $3.05 at the beginning of 2025. Since then, PBYI stock has increased by 16.4% and is now trading at $3.55.

Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.29. The biopharmaceutical company had revenue of $59.10 million for the quarter, compared to analysts' expectations of $52.50 million. Puma Biotechnology had a trailing twelve-month return on equity of 49.35% and a net margin of 16.37%.
Read the conference call transcript
.

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA).

Company Calendar

Last Earnings
2/27/2025
Today
7/03/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PBYI
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+97.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
4.61
Forward P/E Ratio
11.45
P/E Growth
N/A
Net Income
$30.28 million
Pretax Margin
13.73%

Debt

Sales & Book Value

Annual Sales
$230.50 million
Cash Flow
$0.85 per share
Price / Cash Flow
4.18
Book Value
$1.88 per share
Price / Book
1.89

Miscellaneous

Free Float
38,067,000
Market Cap
$176.19 million
Optionable
Optionable
Beta
1.29

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:PBYI) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners